Amyotrophic lateral sclerosis (ALS), better known as Lou Gehrig’s disease, was first identified way back in 1869 but today, more than 150 years later, there are still no effective treatments for it. Now a project, funded by CIRM, has been given approval by the Food and Drug Administration (FDA) to start a clinical trial that … Continue reading Ingenious CIRM-funded stem cell approach to treating ALS gets go-ahead to start clinical trial
Food and Drug Administration
Creating a “Pitching Machine” to speed up our delivery of stem cell treatments to patients
When baseball players are trying to improve their hitting they’ll use a pitching machine to help them fine tune their stroke. Having a device that delivers a ball at a consistent speed can help a batter be more consistent and effective in their swing, and hopefully get more hits. That’s what we are hoping our … Continue reading Creating a “Pitching Machine” to speed up our delivery of stem cell treatments to patients
Funding stem cell research targeting a rare and life-threatening disease in children
If you have never heard of cystinosis you should consider yourself fortunate. It’s a rare condition caused by an inherited genetic mutation. It hits early and it hits hard. Children with cystinosis are usually diagnosed before age 2 and are in end-stage kidney failure by the time they are 9. If that’s not bad enough … Continue reading Funding stem cell research targeting a rare and life-threatening disease in children
Asterias’ stem cell clinical trial shows encouraging results for spinal cord injury patients
When researchers are carrying out a clinical trial they have two goals: first, show that it is safe (the old “do no harm” maxim) and second, show it works. One without the other doesn’t do anyone any good in the long run. A few weeks ago Asterias Biotherapeutics showed that their CIRM-funded stem cell therapy … Continue reading Asterias’ stem cell clinical trial shows encouraging results for spinal cord injury patients
CIRM’s Randy Mills: New FDA rules for stem cells won’t fix the problem
For the last two days the Food and Drug Administration (FDA) has been holding a hearing in Bethesda, Maryland on new regulations that would tighten control over stem cell treatments. The FDA invited public testimony during the hearing on the regulations that would impact many of the clinics that currently offer unproven therapies The testimony … Continue reading CIRM’s Randy Mills: New FDA rules for stem cells won’t fix the problem
Making a deposit in the Bank: using stem cells from children with rare diseases to find new treatments
Part of The Stem Cellar series on ten years of iPS cells For Chris Waters, the motivation behind her move from big pharmaceutical companies and biotech to starting a non-profit organization focused on rare diseases in children is simple: “What’s most important is empowering patient families and helping them accelerate research to the clinical solutions … Continue reading Making a deposit in the Bank: using stem cells from children with rare diseases to find new treatments
New approach could help turn back the clock and reverse damage for stroke patients
Stroke is the leading cause of serious, long-term disability in the US. Every year almost 800,000 people suffer from a stroke. The impact on their lives, and the lives of those around them can be devastating. Right now the only treatment approved by the US Food and Drug Administration (FDA) is tissue plasminogen activator or … Continue reading New approach could help turn back the clock and reverse damage for stroke patients
A look back at the last year – but with our eyes firmly on the future
Better. With that single word Randy Mills, our President and CEO, starts and ends his letter in our 2015 Annual Report and lays out the simple principle that guides the way we work at CIRM. Better. But better what? “Better infrastructure to translate early stage ideas into groundbreaking clinical trials. Better regulatory practices to advance … Continue reading A look back at the last year – but with our eyes firmly on the future
CIRM-funded stem cell clinical trial for retinitis pigmentosa focuses on next stage
How retinitis pigmentosa erodes normal vision The failure rate for clinical trials is depressingly high. A study from Tufts University in 2010 found that for small molecules – the substances that make up more than 90 percent of the drugs on the market today – the odds of getting from a Phase 1 trial to … Continue reading CIRM-funded stem cell clinical trial for retinitis pigmentosa focuses on next stage
The Spanish Inquisition and a tale of two stem cell agencies
Monty Python's Spanish Inquisition sketch: Photo courtesy Daily Mail UK It’s not often an article on stem cell research brings the old, but still much loved, British comedy series Monty Python into the discussion but a new study in the journal Cell Stem Cell does just that, comparing the impact of CIRM and the UK’s … Continue reading The Spanish Inquisition and a tale of two stem cell agencies
The Stem Cellar 